Medco Research
Executive Summary
Acquires Robins' antihypertensive Tenathan (bethanidine). Approved in 1981 for the treatment of hypertension, Tenathan has never been marketed in the U.S. Medco says it "intends to test bethandidine in the prevention and treatment of ventricular fibrillation," with clinical studies beginning "in the near future." Robins retains right to manufacture and market the product under a royalty agreement.
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: